| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14656566.2010.494598 |
| P698 | PubMed publication ID | 20629607 |
| P2093 | author name string | Clete Kushida | |
| Susan Imamura | |||
| P2860 | cites work | Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials | Q33413352 |
| Pathological gambling caused by drugs used to treat Parkinson disease | Q33988551 | ||
| Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. | Q34044826 | ||
| The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil | Q34097242 | ||
| XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters | Q34321050 | ||
| XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkey | Q34321054 | ||
| Restless legs syndrome prevalence and impact: REST general population study | Q34426489 | ||
| Prevalence of restless legs syndrome and periodic limb movement disorder in the general population | Q34525455 | ||
| Autosomal dominant restless legs syndrome maps on chromosome 14q. | Q34533932 | ||
| Linkage analysis identifies a novel locus for restless legs syndrome on chromosome 2q in a South Tyrolean population isolate | Q34564654 | ||
| A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13. | Q34565302 | ||
| A genetic risk factor for periodic limb movements in sleep | Q34651669 | ||
| Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions | Q34653028 | ||
| Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin | Q34841404 | ||
| Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice | Q34858059 | ||
| Accommodating chromosome inversions in linkage analysis | Q35015731 | ||
| Pramipexole for the treatment of restless legs syndrome | Q36407375 | ||
| A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome | Q37244788 | ||
| Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome | Q43202454 | ||
| Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial | Q43294942 | ||
| Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study | Q44228579 | ||
| Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). | Q44729978 | ||
| Long-term treatment of restless legs syndrome with dopamine agonists | Q45056935 | ||
| Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. | Q46135857 | ||
| A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome | Q48398969 | ||
| Restless legs syndrome: diagnosis, epidemiology, classification and consequences | Q48479960 | ||
| Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study | Q48591904 | ||
| Restless legs syndrome: a clinical study of 55 patients | Q48701164 | ||
| Prevalences of periodic limb movement-like and restless legs-like symptoms among Japanese adults | Q48704536 | ||
| A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. | Q48730830 | ||
| Clonazepam and vibration in restless legs syndrome | Q49076085 | ||
| Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. | Q53242298 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dopamine | Q170304 |
| gabapentin enacarbil | Q5515257 | ||
| gabapentin | Q410352 | ||
| restless legs syndrome | Q916280 | ||
| P304 | page(s) | 1925-1932 | |
| P577 | publication date | 2010-08-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Gabapentin enacarbil (XP13512/GSK1838262) as an alternative treatment to dopaminergic agents for restless legs syndrome | |
| P478 | volume | 11 |
| Q38122149 | Gabapentin enacarbil: pharmacotherapy of restless legs syndrome | cites work | P2860 |
Search more.